RE:RE:RE:RE:RE:Functional Drink and moreFrom the 2017 Q1 MD&A "While Q1, 2017 has shown a decrease in sales compared to Q1, 2016, we expect our base business in cosmeceuticals to remain solid over the next 12 months." A "solid" outlook resulted in decreasing sales, so I wouldn't put any comfort in them saying they expect a solid year.
Beta glucan trial still hasn't even started after how many years? I wouldn't put much value in that at the pace the company is going.
The functional drink is about the only thing that may drive value, however how much it is actually worth is very difficult to determine. No contracts yet...
digitel wrote: "Sales are dropping. No indication that there is increased demand. There could be, but saying that no one has proven there isn't more demand is not a good reason for shareholders to invest in a company."
Sales have always fluctuated based upon when orders are placed.
CZO has talked to its distribution partners and expects a solid year.
Then add the functional drink expected by year-end and the value of the beta glucan trial.
“On the financial front, our fundamentals remain solid despite lower results than the comparative quarter in 2017. Following strategic discussions with our distribution partners and given the recently completed integration of JuventeDC, we remain confident we will deliver another solid year while transforming our business model from a contract manufacturer to a biopharmaceutical company,” concluded Mr. Gagnon.
Read more at https://www.stockhouse.com/news/press-releases/2018/05/17/ceapro-inc-reports-2018-first-quarter-results#8WRJXpR8Ki2v7lyf.99